NATTOPHARMA & CARDIOVASCULAR RESEARCH INSTITUTE MAASTRICHT RENEW LONG-STANDING VITAMIN K2 RESEARCH PARTNERSHIP
Renewed five-year commitment kicks-off with research project that aims to verify severe vitamin K deficiency in COVID-19 patients and to demonstrate that vitamin K2 may provide a novel solution for optimizing vascular health.OSLO (1 DECEMBER 2020) — In 2006, NattoPharma began a research partnership with the University of Maastricht, the Netherlands, the distinguished group that continues to lead the exploration of K2 discovery and its role in improving human health. This has resulted in many successes, such as partnership in the Horizon 2020 EU ITN grants EVOluTION and INTRICARE and